Story

Attovia Therapeutics Raises $332.4 Million in Nasdaq IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
Attovia Therapeutics Raises $332.4 Million in Nasdaq IPO
Text size
Background

Clinical-stage biopharmaceutical company Attovia Therapeutics (Nasdaq: ATTO) has successfully closed its initial public offering, raising approximately $332.4 million in gross proceeds before underwriting discounts and other expenses. The company's shares began trading on the Nasdaq Global Market on August 5, 2026.

Offering Details

The San Carlos, California-based company sold a total of 19,550,000 shares at a public offering price of $17.00 per share. According to the announcement, all shares were offered by Attovia.

The final share count includes the full exercise of the underwriters’ option to purchase an additional 2,550,000 shares, which contributed to the total proceeds raised. The offering officially closed on August 6, 2026.

Market Debut and Underwriters

The U.S. Securities and Exchange Commission (SEC) declared the registration statement for the offering effective on August 4, 2026, paving the way for the market debut. A consortium of investment banks managed the transaction.

Sample IUX Markets – In-articleAd

Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets acted as joint book-running managers for the offering. LifeSci Capital served as a passive book-running manager.

Company Pipeline

Attovia Therapeutics focuses on developing novel treatments for inflammatory and immune-mediated diseases. The capital raised from the IPO is expected to help advance its development pipeline, which includes:

  • ATTO-1310: An anti-IL-31 therapeutic currently in clinical development for chronic pruritic diseases.
  • ATTO-2306: A bispecific antibody targeting IL-31 and IL-13 for atopic dermatitis, which is in IND-enabling studies.
  • ATTO-1091: A trispecific antibody for inflammatory bowel disease, also in IND-enabling studies.

Read next

More on Stocks
Back to latest news

LATEST